| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Vanessa Sanchez-Gistau, María José Moreno, Susana Gómez-Lus, Antoni Sicras-Mainar, Benedicto Crespo-Facorr. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study. Frontiers in psychiatry. vol 14. 2023-08-21. PMID:37599866. |
this study aims to compare the hospitalization rate in individuals with schizophrenia who started their treatment with aripiprazole once monthly (aom400) or atypical oral antipsychotics (oa) in spain. |
2023-08-21 |
2023-09-07 |
Not clear |
| Cailian Lu, Shan Li, Lin Kang, Qianqian Li, Hongxu Chen, Yanwen Lin, Han Zhang, Ziling Tang, Meiyan Bai, Peng Xion. Aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model. Neuroscience letters. 2023-07-26. PMID:37495071. |
aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model. |
2023-07-26 |
2023-08-14 |
mouse |
| Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. |
genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. |
2023-07-25 |
2023-08-14 |
Not clear |
| Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. |
aripiprazole is recommended for routine use in schizophrenia patients. |
2023-07-25 |
2023-08-14 |
Not clear |
| Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. |
however, the biological mechanism for the adverse drug reactions (adrs) among schizophrenia patients with the antipsychotic drug aripiprazole is far from clear. |
2023-07-25 |
2023-08-14 |
Not clear |
| Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. |
to explore the potential genetic factors that may cause movement-related adverse antipsychotic effects in patients, we conducted an association analysis between movement-related adrs and snps in schizophrenia patients receiving aripiprazole monotherapy. |
2023-07-25 |
2023-08-14 |
Not clear |
| Gabriel D Flores-Gómez, David Javier Apam-Castillejos, Ismael Juárez-Díaz, Estefania Fuentes-Medel, Alfonso Díaz, Hiram Tendilla-Beltrán, Gonzalo Flore. Aripiprazole attenuates the medial prefrontal cortex morphological and biochemical alterations in rats with neonatal ventral hippocampus lesion. Journal of chemical neuroanatomy. 2023-07-22. PMID:37481172. |
in this study, it was evaluated the effect of the atypical antipsychotic aripiprazole (ari) on the behavioral and mpfc neuronal disturbances of rats with neonatal ventral hippocampus lesion (nvhl), which is a heuristic developmental model relevant to the study of schizophrenia. |
2023-07-22 |
2023-08-14 |
rat |
| Pierre Baumann, Philipp Bauknecht, Maxim Kuzin, Georgios Schoretsaniti. Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review. International journal of psychiatry in clinical practice. 2023-07-10. PMID:37428441. |
the aim of this review is to analyse the literature regarding studies centred on the clinical outcome of individuals affected by schizophrenia and treated with various antipsychotics, and then switched to orally administered partial d2-dopamine agonists (pd2a): aripiprazole (ari), brexpiprazole (brex) or cariprazine (cari). |
2023-07-10 |
2023-08-14 |
Not clear |
| Fumiaki Yamasaki, Nobuhisa Kanahara, Yusuke Nakata, Shinji Koyoshi, Yuta Yanagisawa, Takeru Saito, Takahiro Oiwa, Masanobu Kogure, Tsuyoshi Sasaki, Taisuke Yoshida, Hiroshi Kimura, Masaomi Iy. Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice. Journal of psychopharmacology (Oxford, England). 2023-07-03. PMID:37395368. |
several studies have reported that a switch to the dopamine partial agonist (dpa) aripiprazole (arp), especially when the switch is abrupt, is likely to fail and sometimes worsen psychosis in schizophrenia patients already under high-dose antipsychotic treatment. |
2023-07-03 |
2023-08-14 |
Not clear |
| Manoj Kumar Sahoo, Harshita Biswas, Sandeep Grove. Safety Profile of Aripiprazole During Pregnancy and Lactation: Report of 2 Cases. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 34. issue 2. 2023-06-26. PMID:37357900. |
aripiprazole, a second-generation antipsychotic (sga) medication, is an efficacious treatment for schizophrenia and bipolar disorder. |
2023-06-26 |
2023-08-14 |
Not clear |
| Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S Bell Lynum, Sanjeda R Chumki, Heather Fitzgerald, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Moeen Panni, Stephen R Sakla. Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison. Neuropsychiatric disease and treatment. vol 19. 2023-06-14. PMID:37313228. |
aripiprazole 2-month ready-to-use 960 mg (ari 2mrtu 960) is a novel long-acting injectable (lai) formulation of aripiprazole monohydrate for administration once every 2 months, developed for the treatment of schizophrenia or maintenance monotherapy treatment of bipolar i disorder in adults (indication will vary by country). |
2023-06-14 |
2023-08-14 |
Not clear |
| Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S Bell Lynum, Sanjeda R Chumki, Heather Fitzgerald, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Moeen Panni, Stephen R Sakla. Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison. Neuropsychiatric disease and treatment. vol 19. 2023-06-14. PMID:37313228. |
aripiprazole lauroxil 1064 mg (al 1064) is an lai formulation of aripiprazole lauroxil, an aripiprazole prodrug, for administration once every 2 months, indicated for the treatment of schizophrenia in adults. |
2023-06-14 |
2023-08-14 |
Not clear |
| Oloruntoba Oluboka, Guerline Clerzius, Wolfgang Janetzky, Daniel Schöttle, François Therrien, Klaus Wiedemann, Marc-André Ro. Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study). BMC psychiatry. vol 23. issue 1. 2023-05-31. PMID:37259053. |
improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (react study). |
2023-05-31 |
2023-08-14 |
Not clear |
| Avijeet S Chopra, Dusica Hadzi Boskovic, Amit Kulkarni, Jeffrey M Cochra. Cost-Effectiveness of Aripiprazole Tablets with Sensor versus Oral Atypical Antipsychotics for the Treatment of Schizophrenia Using a Patient-Level Microsimulation Modeling Approach. ClinicoEconomics and outcomes research : CEOR. vol 15. 2023-05-30. PMID:37252199. |
cost-effectiveness of aripiprazole tablets with sensor versus oral atypical antipsychotics for the treatment of schizophrenia using a patient-level microsimulation modeling approach. |
2023-05-30 |
2023-08-14 |
Not clear |
| Tianhang Zhou, Chengcheng Pu, Zetao Huang, Tianqi Gao, Enpeng Zhou, Yue Zheng, Dan Zhang, Bingjie Huang, Zhang Cheng, Chuan Shi, Xin Y. Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. Asian journal of psychiatry. vol 84. 2023-04-24. PMID:37094459. |
weight changes following treatment with aripiprazole, risperidone and olanzapine: a 12-month study of first-episode schizophrenia patients in china. |
2023-04-24 |
2023-08-14 |
Not clear |
| Tianhang Zhou, Chengcheng Pu, Zetao Huang, Tianqi Gao, Enpeng Zhou, Yue Zheng, Dan Zhang, Bingjie Huang, Zhang Cheng, Chuan Shi, Xin Y. Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. Asian journal of psychiatry. vol 84. 2023-04-24. PMID:37094459. |
this study aimed to assess weight changes following antipsychotic treatment in first-episode schizophrenia (fes) patients and make a comparison of aripiprazole, risperidone and olanzapine. |
2023-04-24 |
2023-08-14 |
Not clear |
| Eirik Kjelby, Rolf Gjestad, Farivar Fathian, Igne Sinkeviciute, Renata Alisauskiene, Liss Anda, Else-Marie Løberg, Solveig Klæbo Reitan, Inge Joa, Tor Ketil Larsen, Maria Rettenbacher, Jan Øystein Berle, Ole Bernt Fasmer, Rune Andreas Kroken, Erik Johnse. Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro). Journal of clinical psychopharmacology. 2023-04-21. PMID:37083542. |
consequently, in a 12-month pragmatic, randomized clinical trial, we aimed to investigate differences in antidepressive effectiveness among amisulpride, aripiprazole, and olanzapine as a secondary outcome, measured by change in the calgary depression scale for schizophrenia sum score in patients within the schizophrenia spectrum. |
2023-04-21 |
2023-08-14 |
Not clear |
| Małgorzata Janas-Kozik, Dominika Dudek, Janusz Heitzman, Barbara Remberk, Jerzy Samochowiec, Agnieszka Słopień, Adam Wichnia. Polish Psychiatric Association diagnostic and therapeutic management guidelines for patients with early-onset schizophrenia. Psychiatria polska. vol 56. issue 4. 2023-04-19. PMID:37074823. |
second-generation antipsychotic agents approved for the treatment of early-onset schizophrenia - aripiprazole, lurasidone and paliperidone - enable its effective and safe treatment. |
2023-04-19 |
2023-08-14 |
Not clear |
| Qian Li, Yun'Ai Su, Xuemei Liao, Maosheng Fang, Jianliang Gao, Jia Xu, Mingjun Duan, Haiying Yu, Yang Yang, Zhiyu Chen, Jintong Liu, Shaoxiao Yan, Peifen Yao, Shuying Li, Changhong Wang, Bin Wu, Congpei Zhang, Tianmei S. Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China. Chinese medical journal. 2023-04-04. PMID:37014776. |
aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in china. |
2023-04-04 |
2023-08-14 |
Not clear |
| Claudio Brasso, Gianluca Colli, Rodolfo Sgro, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Vincenzo Villari, Paola Rocc. Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review. Biomedicines. vol 11. issue 3. 2023-03-29. PMID:36979900. |
serotonin-dopamine activity modulators (sdams), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce ns. |
2023-03-29 |
2023-08-14 |
Not clear |